



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/803,459
		Filing Date	March 19, 2004
		First Named Inventor	Gertler
		Art Unit	1614 1647
		Examiner Name	Ian Dang
Sheet 1	of 4	Attorney Docket Number	28758.74

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/I.D./	10	SANDOWSKI ET AL., J. Biological Chemistry, November 29, 2002, pages 46304-46309, Vol. 277 (48), USA.	
	11	HANIU ET AL., J. Biological Chemistry, October 30, 1998, pages 28691-28699, Vol. 273 (44), USA.	
	12	FONG ET AL., Molecular Pharmacology, 1998, pages 234-240, Vol. 53, USA.	
	13	GAVRILOVA ET AL., J. Biological Chemistry, November 28, 1997, pages 30546-30551, Vol. 272 (48), USA.	
	14	LIU ET AL., Endocrinology, 1997, pages 3548-3554, Vol. 138 (8), USA.	
	15	DEVOS ET AL., J. Biological Chemistry, July 18, 1997, pages 18304-18310, Vol. 272 (29), USA.	
	16	KRATZSCH ET AL., Hormone Research, 2002, pages 127-132, Vol. 57, USA.	
	17	DRIDI ET AL., Am. J. Physio. Endocrinol. Metab., 2000, pages E116-E123, Vol. 279, USA.	
	18	WU ET AL., J. Clinical Endocrinol. Metab., 2002, pages 2931-2939, Vol. 87 (6), USA.	
↓	19	BAUMGARTNER ET AL., J. Biological Chemistry, November 18, 1994, pages 29094-29101, Vol. 269 (46), USA.	

Examiner Signature	/Ian Dang/	Date Considered	11/15/2007
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/803,459
				Filing Date	March 19, 2004
				First Named Inventor	Gertler
				Art Unit	1614 1647
				Examiner Name	Ian Dang
Sheet 2	of 4	Attorney Docket Number	28758.74		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/I.D./	20	SINHA ET AL., J. Clinical Investigation, September 1996, pages 1277-1282, Vol. 98 (6), USA.		
	21	MAAMRA ET AL., Endocrinology, 2001, pages 4389-4393, Vol. 142 (10), USA.		
	22	RAVER ET AL., Experimental Biology 2003 Meeting Abstract, April 2003, Abstract No. 571.1, USA.		
	23	OHKUBO ET AL., Biochimica et Biophysica Acta, 2000, pages 303-308, Vol. 1491, USA.		
	24	FONG ET AL., Molecular Pharmacology, 1998, pages 234-240, Vol. 53, USA.		
	25	HOREV ET AL., Molecular and Cellular Endocrinology, 2000, pages 95-106, Vol. 162, USA.		
	26	TARTAGLIA ET AL., Cell, December 29, 1995, pages 1263-1272, Vol. 83, USA.		
	27	TAKAYA ET AL., Biochemical and Biophysical Research Communications, 1996, pages 75-83, Vol. 225, USA.		
	28	HENSON ET AL., Biology of Reproduction, 2000, pages 1219-1228, Vol. 63, USA.		
↓	29	TARTAGLIA, J. Biological Chemistry, March 7, 1997, pages 6093-6096, Vol. 272 (10), USA.		

Examiner Signature	/Ian Dang/	Date Considered	11/15/2007
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/803,459
				Filing Date	March 19, 2004
				First Named Inventor	Gertler
				Art Unit	4644 1647
				Examiner Name	Ian Dang
Sheet	3	of	4	Attorney Docket Number	28758.74

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/I.D./	30	JANECKOVA, Physiol. Res., 2001, pages 4430459, Vol. 50, USA		
	31	BRADLEY ET AL., Recent Prog. Horm. Res., 2001, pages 329-358, Vol. 56, USA.		
	32	HUANG ET AL., Cell Research, 2000, pages 81-92, Vol. 10, USA.		
	33	HOUSEKNECHT ET AL., Diabetes, 1996, pages 1638-1643, Vol. 45 (11), USA.		
	34	LUOH ET AL., J. Molecular Endocrinology, 1997, pages 77-85, Abstract, Vol. 18 (1), USA		
	35	TAOUIS ET AL., Gene, February 22, 1998, pages 239-242, Vol. 208 (2), USA.		
	36	ROCK ET AL., Horm. Metab. Res., December 1996, pages 748-750, Vol. 28 (12), USA.		
	37	GERTLER ET AL., FEBS Lett., January 30, 1998, pages 137-140, Vol. 422 (2), USA.		
	38	RAVER ET AL., Gen. Comp. Endocrinol., March 2002, pages 52-58, Abstract, Vol. 126 (1), USA.		
↓	39	TAOUIS ET AL., Domest. Anim. Endocrinol., November 2001, pages 319-327, Abstract, Vol. 21 (4), USA.		

Examiner Signature	/Ian Dang/	Date Considered	11/15/2007
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/803,459
				Filing Date	March 19, 2004
				First Named Inventor	Gertler
				Art Unit	1614 1647
				Examiner Name	Ian Dang
Sheet	4	of	4	Attorney Docket Number	28758.74

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/I.D./	40	RAVER ET AL., Protein Expr. Purif., June 2000, pages 30-40, Abstract, Vol. 19 (1), USA.			
	41	RAVER ET AL., Protein Expr. Purif., December 1998, pages 403-408, Abstract, Vol. 14 (3), USA.			
	42	RICHARDS ET AL., Comp. Biochem. Physiol. B. Biochem. Mol. Biol., December 2003, pages 833-847, Abstract, Vol. 136 (4), USA.			
	43	GONZALEZ ET AL., Endocrine, July 2003, pages 185-195, Vol. 21 (2), USA.			
	44	YIANNAKOURIS ET AL., J. Clin. Endocrinol. & Metab., 2001, pages 4434-4439, Vol. 86 (9), USA.			
↓	45	KIESS ET AL., J. Clin. Endocrinol. & Metab., 2001, pages 4472-4479, Vol. 86 (9), USA.			

Examiner Signature	/ian Dang/	Date Considered	11/15/2007
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.